Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells
Y Sohara, H Shimada, C Minkin, A Erdreich-Epstein… - Cancer research, 2005 - AACR
Cancer research, 2005•AACR
The bone is the third most common site of cancer metastasis. To invade the bone, tumor
cells produce osteoclast-activating factors that increase bone resorption by osteoclasts.
Here we report that human neuroblastoma cells that form osteolytic lesions in vivo do not
produce osteoclast-activating factors but rather stimulate osteoclast activity in the presence
of human bone marrow mesenchymal stem cells. This alternative pathway of osteoclast
activation involves a nonadhesive interaction between neuroblastoma cells and bone …
cells produce osteoclast-activating factors that increase bone resorption by osteoclasts.
Here we report that human neuroblastoma cells that form osteolytic lesions in vivo do not
produce osteoclast-activating factors but rather stimulate osteoclast activity in the presence
of human bone marrow mesenchymal stem cells. This alternative pathway of osteoclast
activation involves a nonadhesive interaction between neuroblastoma cells and bone …
Abstract
The bone is the third most common site of cancer metastasis. To invade the bone, tumor cells produce osteoclast-activating factors that increase bone resorption by osteoclasts. Here we report that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-activating factors but rather stimulate osteoclast activity in the presence of human bone marrow mesenchymal stem cells. This alternative pathway of osteoclast activation involves a nonadhesive interaction between neuroblastoma cells and bone marrow mesenchymal stem cells. Stimulated bone marrow mesenchymal stem cells express markedly increased levels of interleukin-6, which is then responsible for osteoclast activation. This report describes a critical role of bone marrow mesenchymal stem cells in bone destruction in cancer.
AACR